Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-019 booster in healthy Japanese adults
NCT05299359Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2022
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19), sponsored by Takeda. Started Apr 2022; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05299359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299359.